TCI Wealth Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

TCI Wealth Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-193	Closed	-$3.32K	–	2304
2023 Q1	$3.32K	Buy	+193	New	+$3.91K	﹤0.01%	1797
2022 Q1	–	Sell	-63	Closed	-$5K	–	2493
2021 Q4	$5K	Hold	63	–	–	﹤0.01%	1739
2021 Q3	$4K	Buy	63 +18	+40%	+$1.04K	﹤0.01%	1842
2021 Q2	$2K	Buy	45 +3	+7%	+$161	﹤0.01%	2119
2021 Q1	$2K	Buy	+42	New	+$1.81K	﹤0.01%	1934

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCI Wealth Advisors's ZNTL Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2023, closing a stake of 193 shares — an estimated $3.32K sold.

TCI Wealth Advisors first reported a position in ZNTL in Q1 2021 and held it in 5 quarters. The position peaked at $5K in Q4 2021. 134 funds tracked by Wall St. Rank hold ZNTL as of Q2 2023.

TCI Wealth Advisors reported no remaining Zentalis Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 193 Zentalis Pharmaceuticals shares in Q2 2023, an estimated $3.32K.
TCI Wealth Advisors first reported a position in Zentalis Pharmaceuticals in Q1 2021 and held it in 5 quarters.
TCI Wealth Advisors's Zentalis Pharmaceuticals position peaked at $5K in Q4 2021.
134 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.